Mitral Valve Disease Global Market Report 2024

Mitral valve disease affects the mitral valve, which regulates blood flow between the heart's left atrium and left ventricle. This disorder can cause narrowing or leakage of the valve, disrupting normal blood circulation and leading to symptoms such as breathlessness, fatigue, and irregular heart rhythms. The primary goal in managing mitral valve disease is to maintain proper blood flow through the heart and prevent complications.

Key treatments for mitral valve disease include mitral valve repair, mitral valve replacement, cardiac resynchronization therapy, and mitral valve therapeutics. Mitral valve repair involves surgical or minimally invasive procedures to correct defects or leaks in the mitral valve, aiming to restore its normal function and prevent further health issues. This treatment is used to address conditions such as mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation, and is administered in settings such as hospitals and ambulatory surgical centers.

The mitral valve disease market research report is one of a series of new reports that provides mitral valve disease market statistics, including the mitral valve disease industry global market size, regional shares, competitors with mitral valve disease market share, detailed mitral valve disease market segments, market trends, and opportunities, and any further data you may need to thrive in the mitral valve disease industry. These mitral valve disease market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The mitral valve disease market size has grown strongly in recent years. It will grow from $2.75 billion in 2023 to $3 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historic period can be credited to several factors including initiatives focused on patient education, favorable reimbursement policies and insurance coverage, increased healthcare spending, heightened awareness and screening campaigns, as well as expanded market penetration efforts.

The mitral valve disease market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The anticipated growth in the forecast period can be attributed to several key factors. These include the rising prevalence of mitral valve disease, growing adoption of minimally invasive techniques, continuous innovations in heart valve surgery, increased venture capital investments, and heightened interest among manufacturers. Major trends expected during this period encompass advancements in technology, particularly in transcatheter technologies, and continuous improvements in surgical procedures.

The mitral valve disease market is poised for growth due to the increasing prevalence of vascular heart diseases. Vascular heart diseases encompass various conditions affecting the heart's blood vessels, either supplying it or within the heart itself. Factors driving this rise include lifestyle choices, demographic shifts, medical conditions, environmental influences, and genetic factors. Conditions such as ischemic heart disease and hypertension, part of vascular heart diseases, can indirectly lead to mitral valve disease by compromising heart structure and function. For instance, recent data from the Australian Bureau of Statistics in December 2023 indicated that around 571,000 adults aged 18 and older in Australia were living with coronary heart disease (CHD), constituting 2.9% of the adult population. The prevalence of CHD increases notably with age, affecting approximately 11% of adults aged 75 and above. This trend underscores how vascular heart diseases contribute to the growing incidence of mitral valve disease.

Key players in the mitral valve disease market are focusing on developing stented tissue valves to meet the rising demand for minimally invasive treatment options. These valves are designed to offer durable performance and are considered alternatives to traditional surgical interventions. For example, Abbott Laboratories received FDA approval in September 2021 for Epic Plus and Epic Plus Supra stented tissue valves, designed for treating aortic or mitral valve disease. These devices utilize Abbott's Epic surgical valve platform and include anti-calcification technology. They feature a FlexFit polymer stent capable of withstanding pressures during balloon valvuloplasty, a pericardial shield to reduce abrasion risk, and a flexible cuff to minimize paravalvular leaks and accommodate patient anatomy.

In June 2021, Gyrus Capital acquired LivaNova PLC's heart valve business for $73 million. This acquisition encompassed LivaNova's heart valve products, such as the Perceval sutureless aortic valve and the Memo 4D mitral repair ring, along with their global operations. LivaNova PLC, a UK-based medical technology company specializing in cardiovascular diseases, including aortic valve disease, continues to be a key player in the industry.

Major companies operating in the mitral valve disease market are Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences, ShockWave Medical Inc., Artivion Inc., TTK Health Care Limited, Braile Biomedica, JenaValve Technology Inc., 4C Medical technologies, Labcor Laboratorios Ltda, CryoLife Inc., Valcare Medical, Affluent Medical, Colibri Heart Valve LLC, Coramaze Technologies, Corcym UK Limited, HighLife Medical, Micro International Devices Inc., Neovasc Inc., Mitralign Inc., Transcatheter Technologies GmbH.

Europe was the largest region in the mitral valve disease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mitral valve disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mitral valve disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mitral valve disease market includes revenues earned by entities by providing services such as diagnostic imaging, surgical, and interventional procedures, alongside consultation, rehabilitation, and telemedicine services, catering to patient care and research needs. The market value includes the value of related goods sold by the service provider or included within the service offering. The mitral valve disease market also includes sales of valve repair devices, valve replacement devices, imaging and diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.